



Co-Founder

Azure Cell Therapies
Geneva, Switzerland



BILAL

FARES

Biotech Entrepreneur/
Neurodegenerative
Diseases

Education & Training

DOCTOR OF PHILOSOPHY

2010 - 2015
Biotechnology and Bioengineering
EPFL - Lausanne, Switzerland

POSTDOCTORAL FELLOW

2015-2016
Lashuel Lab
EPFL - Lausanne, Switzerland

POSTDOCTORAL FELLOW/STUDY DIRECTOR

2017-2019
Philip Morris International
Switzerland

CO-FOUNDER / DIRECTOR OF R&D

2019 - 2023
ND BioSciences
Lausanne, Switzerland

CO-FOUNDER

2024 - Present
Azure Cell Therapies
Geneva, Switzerland

Profile

Dr. Bilal Fares completed his PhD at EPFL, specializing in Parkinson's disease (PD) research. He co-founded ND Biosciences in 2019, focusing on developing therapeutics and diagnostics for neurodegenerative diseases, raising CHF 3 million, and launching commercial products globally.

In 2024, he co-founded Azure Cell Therapies, leveraging CHF 8 million in grant funding and seven patents to develop regenerative stem cell therapies for PD. Bilal has also completed an MBA, adding strategic business expertise to his scientific background.

Articles

Comparative Analysis of Total Alpha-Synuclein (α SYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified α SYN Proteoforms

Press

ND Biosciences: The Venture Leader Biotech developing therapies for neurodegenerative diseases



[linkedin.com/in/b-fares](https://www.linkedin.com/in/b-fares)



m.bilal.fares@gmail.com